An updated edition of the March 26, 2026, article. The global oncology market is undergoing rapid transformation, driven by rising cancer incidence, aging population and ongoing scientific advances.

Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve ...

Erasca (NASDAQ:ERAS) executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic and ...

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-1181 ...

New cancer trial: Merck and Erasca will test ERAS-0015 with Keytruda in RAS-mutant solid tumors under the AURORAS-1 study. Potential treatment boost: The combination targets tumor pathways and immune ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients ...

The firm is evaluating the combination in a Phase I trial to determine if it improves responses and reduces acquired resistance.

Once-daily vosoritide improved annualized growth velocity at 1 year for children with five different genetic subtypes of ...

Today, STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology announced the launch of the ...

Erasca Inc. (NASDAQ:ERAS) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Erasca announced positive preliminary Phase 1 data for ERAS-0015, a pan-RAS ...